Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Short-term Investments (2020 - 2023)

Ascendis Pharma A (ASND) has disclosed Short-term Investments for 4 consecutive years, with $7.8 million as the latest value for Q4 2023.

  • Quarterly Short-term Investments fell 97.36% to $7.8 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2023, down 97.36% year-over-year, with the annual reading at $7.8 million for FY2023, 97.36% down from the prior year.
  • Short-term Investments hit $7.8 million in Q4 2023 for Ascendis Pharma A, down from $296.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $296.6 million in Q4 2022 to a low of $7.8 million in Q4 2023.
  • Historically, Short-term Investments has averaged $183.6 million across 4 years, with a median of $214.9 million in 2020.
  • Biggest five-year swings in Short-term Investments: surged 68.49% in 2021 and later crashed 97.36% in 2023.
  • Year by year, Short-term Investments stood at $160.1 million in 2020, then surged by 68.49% to $269.7 million in 2021, then increased by 9.95% to $296.6 million in 2022, then plummeted by 97.36% to $7.8 million in 2023.
  • Business Quant data shows Short-term Investments for ASND at $7.8 million in Q4 2023, $296.6 million in Q4 2022, and $269.7 million in Q4 2021.